AIM: To evaluate the methylation status of CDH1, FHIT, MTAP and PLAGL1 promoters and the association of these findings with clinico-pathological characteristics. METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse-type gastric adenocarcinoma samples from individuals in Northern Brazil. Statistical analyses were performed using the chi-square or Fisher's exact test to assess associations between methylation status and clinico-pathological characteristics. RESULTS: Hypermethylation frequencies of CDH1, FHIT, MTAP and PLAGL1 promoter were 98.7%, 53.9%, 23.1% and 29.5%, respectively. Hypermethylation of three or four genes revealed a significant association with diffuse-type gastric cancer compared with nonneoplastic cancer. A higher hypermethylation frequency was significantly associated with H pylori infection in gastric cancers, especially with diffuse-type. Cancer samples without lymph node metastasis showed a higher FHIT hypermethylation frequency. MTAP hypermethylation was associated with H pylori in gastric cancer samples, as well as with diffuse-type compared with intestinal-type. In diffuse-type, MTAP hypermethylation was associated with female gender. CONCLUSION: Our findings show differential gene methylation in tumoral tissue, which allows us to conclude that hypermethylation is associated with gastric carcinogenesis. MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies. The H pylori infectious agent was present in 44.9% of the samples. This infection may be correlated with the carcinogenic process through the gene promoter hypermethylation, especially the MTAP promoter in diffuse-type. A higher H pylori infection in diffuse-type may be due to greater genetic predisposition.
AIM: To evaluate the methylation status of CDH1, FHIT, MTAP and PLAGL1 promoters and the association of these findings with clinico-pathological characteristics. METHODS: Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffuse-type gastric adenocarcinoma samples from individuals in Northern Brazil. Statistical analyses were performed using the chi-square or Fisher's exact test to assess associations between methylation status and clinico-pathological characteristics. RESULTS: Hypermethylation frequencies of CDH1, FHIT, MTAP and PLAGL1 promoter were 98.7%, 53.9%, 23.1% and 29.5%, respectively. Hypermethylation of three or four genes revealed a significant association with diffuse-type gastric cancer compared with nonneoplastic cancer. A higher hypermethylation frequency was significantly associated with H pylori infection in gastric cancers, especially with diffuse-type. Cancer samples without lymph node metastasis showed a higher FHIT hypermethylation frequency. MTAP hypermethylation was associated with H pylori in gastric cancer samples, as well as with diffuse-type compared with intestinal-type. In diffuse-type, MTAP hypermethylation was associated with female gender. CONCLUSION: Our findings show differential gene methylation in tumoral tissue, which allows us to conclude that hypermethylation is associated with gastric carcinogenesis. MTAP promoter hypermethylation can be characterized as a marker of diffuse-type gastric cancer, especially in women and may help in diagnosis, prognosis and therapies. The H pylori infectious agent was present in 44.9% of the samples. This infection may be correlated with the carcinogenic process through the gene promoter hypermethylation, especially the MTAP promoter in diffuse-type. A higher H pylori infection in diffuse-type may be due to greater genetic predisposition.
Authors: E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin Journal: Nature Date: 2000-03-23 Impact factor: 49.962
Authors: D G Huntsman; F Carneiro; F R Lewis; P M MacLeod; A Hayashi; K G Monaghan; R Maung; R Seruca; C E Jackson; C Caldas Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245
Authors: Carmen Berasain; Henar Hevia; Jokin Fernández-Irigoyen; Esther Larrea; Juan Caballería; José M Mato; Jesús Prieto; Fernando J Corrales; Elena R García-Trevijano; Matías A Avila Journal: Biochim Biophys Acta Date: 2004-11-05
Authors: Ahmad L Subhi; Paula Diegelman; Carl W Porter; Baiqing Tang; Zichun J Lu; George D Markham; Warren D Kruger Journal: J Biol Chem Date: 2003-09-23 Impact factor: 5.157
Authors: M Ohta; H Inoue; M G Cotticelli; K Kastury; R Baffa; J Palazzo; Z Siprashvili; M Mori; P McCue; T Druck; C M Croce; K Huebner Journal: Cell Date: 1996-02-23 Impact factor: 41.582
Authors: J Okuzumi; T Yamane; Y Kitao; K Tokiwa; T Yamaguchi; Y Fujita; H Nishino; A Iwashima; T Takahashi Journal: Cancer Res Date: 1991-03-01 Impact factor: 12.701
Authors: Yuwaraj Kadariya; Bu Yin; Baiqing Tang; Susan A Shinton; Eoin P Quinlivan; Xiang Hua; Andres Klein-Szanto; Tahseen I Al-Saleem; Craig H Bassing; Richard R Hardy; Warren D Kruger Journal: Cancer Res Date: 2009-06-30 Impact factor: 12.701
Authors: Scott M Langevin; Roslyn A Stone; Clareann H Bunker; Jennifer R Grandis; Robert W Sobol; Emanuela Taioli Journal: Carcinogenesis Date: 2010-03-02 Impact factor: 4.944